Tissue-directed antibodies and methods of using the same
US-2024342260-A1 · Oct 17, 2024 · US
Cytokine-based fusion proteins for treatment of immune disorders
US10273284B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10273284-B2 |
| Application number | US-201715658475-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 25, 2017 |
| Priority date | Oct 31, 2006 |
| Publication date | Apr 30, 2019 |
| Grant date | Apr 30, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides fusion proteins including an autoimmune antigen, an allergen antigen or an alloantigen, and an anti-inflammatory cytokine. Compositions and methods including the fusion proteins are also provided.
First claim
Opening claim text (preview).
That which is claimed is: 1. A method of eliciting a tolerogenic response in a subject in need thereof, comprising administering to the subject at least one fusion protein, wherein said fusion protein comprises (i) a myelin basic protein (MBP), proteolipid protein (PLP), myelin oligodendrocyte glycoprotein (MOG), myelin-associated oligodendrocytic basic protein (MOBP), and any combination thereof, and (ii) an anti-inflammatory cytokine selected from the group consisting of interleukin (IL) 1 receptor alpha (IL-1RA) IL-2, IL-4, IL-10, IL-13, IL-16, interferon-beta (IFN-β), and any combination thereof. 2. The method of claim 1 , wherein the tolerogenic response modulates an antigen-specific immune response. 3. The method of claim 1 , wherein the tolerogenic response is an active tolerance mechanism or a sustained tolerogenic response.
Assignees
Inventors
Classifications
Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Drugs for immunological or allergic disorders · CPC title
containing a fusion for binding to a cell surface receptor · CPC title
Cytokines; Lymphokines; Interferons · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10273284B2 cover?
- The present invention provides fusion proteins including an autoimmune antigen, an allergen antigen or an alloantigen, and an anti-inflammatory cytokine. Compositions and methods including the fusion proteins are also provided.
- Who is the assignee on this patent?
- Univ East Carolina
- What technology area does this patent fall under?
- Primary CPC classification A61K39/0008. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).